Clinical Trials

With a fresh $150M, Mighty Therapeutics is set to expand its groundbreaking mitochondrial drugs from rare diseases to major conditions like Parkinson's.

Landmark Phase 3 data for HBI-8000 not only offers new hope for melanoma patients but validates a powerful "China-to-global" drug development strategy.

Atrium Therapeutics' clinical trial for a rare cardiomyopathy isn't just a milestone; it's a strategic maneuver signaling the arrival of precision RNA therapies in cardiology.

Elevara Medicines taps biotech veteran Dr. Mai-Britt Zocca to lead its charge against rheumatoid arthritis with a novel drug and $70M in backing.

RWS launches an integrated linguistic validation service, using AI and a single-vendor model to tackle the costly delays plaguing global clinical trials.

Eupraxia Pharmaceuticals is overhauling its leadership and relocating to major biotech hubs, betting it all on its late-stage pipeline and a pivotal trial.

A landmark public-private partnership in Vietnam pioneers bioengineered corneas, promising to restore sight to millions and signaling a new era for ASEAN biotech.

With a new CMO, $50M in fresh capital, and pivotal trials on the horizon, Cue Biopharma makes a strategic bet on an immunology veteran to guide its future.

New research reveals a popular brain training app may reduce key Alzheimer's biomarkers, offering a potential non-drug path to combat neurodegeneration.

Delonix Bioworks is running parallel trials in China and Australia for its MenB vaccine, a strategic gambit that could disrupt a billion-dollar market.

With the appointment of 25-year industry veteran Seth Houston as CEO, Beaconcure signals a major push to scale its 'trusted AI' platform for life sciences.

A Swiss biotech's oral drug just showed it can cross into the human brain and alter its activity, a key de-risking step in a high-stakes pivot.

A novel drug, LM11A-31, paired with advanced brain mapping, shows promise by preserving neural networks, marking a potential shift from targeting plaques.

Backed by $180M, Celea Therapeutics is deploying a bold head-to-head superiority trial, aiming to prove its drug isn't just an alternative but a new standard.

This Monday, Q32 Bio will unveil pivotal data for its alopecia areata drug. For 700,000 Americans, it could mean a new path beyond today's treatments.

A new AI-native platform from Qtis.ai aims to rebuild clinical trial software from the ground up, challenging incumbents by tackling compliance and usability head-on.

Serina Therapeutics' Parkinson's drug SER-252 advances, but the real story is its POZ Platform, a technology that could reshape drug delivery.

As Immunic executives meet investors, the real audience is the future. With pivotal data on its MS drug due this year, the firm is navigating a high-risk path.

A Cambridge medtech firm has formed a global advisory board to fast-track its revolutionary 10-minute stroke test, a strategic move to disrupt pre-hospital care.

With record Q1 sales and key milestones for iDose® TR and Epioxa, all eyes are on Glaukos's July 29 financial release for its next growth chapter.